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ABSTRACT
Objectives: The aim of the study was to investigate serum concentrations of the insulin-like growth factor-1 in women 
with ovarian cancer and healthy controls, and to compare free IGF-1 levels with selected clinical and pathological param-
eters. Correlation analysis was used to measure the following: IGF-1 concentration and Ca125; IGF-1 level and the height 
of the OC patients.
Material and methods: The study included 70 patients with OC and 50 healthy controls. Serum concentrations of free 
IGF-1 were measured in all subjects. Routine diagnostic tests (CBC and USG and Ca125) were performed. 
Results: Significantly higher serum concentrations of free IGF-1 were found in the study group as compared to controls. No 
statistically significant relationships between IGF-1 serum concentrations and tumor differentiation, histological type, and 
disease stage were detected. No statistically significant correlations between IGF-1 and Ca125 level or between IGF-1 and 
growth of OC patients were found. 
Conclusions: Serum IGF-1 participates in the etiopathogenesis of ovarian cancer in menstruating women, while local 
synthesis of this factor and other components of the autocrine loop of the IGF-1 system play a greater role in their post-
menopausal peers.
Key words: ovarian cancer, insulin-like growth factor–1, carcinogenesis
Ginekologia Polska 2018; 89, 1: 13–19
Corresponding author:
Dominika Majchrzak-Baczmańska
Polish Mother’s Memorial Hospital Research Institute
Rzgowska St. 281/289, 93-338 Łódź
tel.: (42) 271 10 00, fax: (42) 271 16 30
e-mail: majchrzak.dominika@gmail.com
INTRODUCTION
Insulin-like growth factor-1 (IGF-1), also known as 
somatomedin 1, is a mitogen which plays a pivotal role 
in the regulation of cell proliferation, differentiation, and 
apoptosis. IGF-1 is a member of a protein family which also 
includes insulin-like growth factor 2 (IGF-2), two types of 
membrane receptors (IGF-1R and IGF-2R), 6 binding prote-
ins (IGFBP 1–6), hydrolyzing proteases, and other reactive 
molecule-binding proteins, which regulate the activity of 
the growth factors [1]. Disturbances in the functioning of 
the IGFBP/IGF/1GF1R system may lead to the induction of 
carcinogenesis, which has been demonstrated in various 
types of malignancies, i.e. breast, prostate, or colon cancer. 
Both, increased activity of the IGF-1/IGF-1R complex and 
lowered IGF-BP expression have been mentioned among 
the promoting factors for neoplastic processes [1]. IGF-1 is 
believed to exert its mitogenic effect on various cells by 
stimulating their proliferation and inhibiting their apoptosis 
via endocrine, paracrine and autocrine mechanisms [1]. 
Regardless, the findings of various studies which evaluated 
the role of IGF-1 in the biology of ovarian cancer (OC) remain 
ambiguous and often conflicting.
OBJECTIVES
The aim of the study was to investigate serum concen-
trations of free IGF-1 in women with OC vs. healthy controls, 
and to compare serum free IGF-1 levels with selected clinical 
and pathological parameters. Also, correlation analysis was 
used to measure the following: i) serum free IGF-1 concen-
trations and Ca125; ii) serum free IGF-1 levels and height of 
the OC patients. 
MATERIAL AND METHODS
Patient characteristics and inclusion criteria
A total of 120 (70 with OC and 50 healthy controls) pa-
tients of the Clinic of Surgical, Endoscopic and Oncologic 
Gynecology, Polish Mother’s Memorial Hospital in Lodz, 
constituted the study population. Local Ethics Committee 
approved of the study (no: 71/2012). Serum free IGF-1 levels 
were measured in all subjects, followed by routine diagno-
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stic tests: CBC and USG (both groups), and Ca125 (study 
group). Informed consent was obtained from all patients. All 
subjects from the study group were treated in accordance 
with the oncologic protocol. The exclusion criteria were as 
follows: history of chemotherapy or radiotherapy due to 
malignant neoplasms, history of any malignancy, recur-
rent OC (only patients with primary OC with no previous 
treatment were included), and hormonal therapy (contra-
ceptives, HRT, etc.).
Immunoenzymatic analysis  
of serum free IGF-1 concentration
In the morning, 5 mL of fasting blood samples were 
drawn into serum gel tubes and transported to the labora-
tory within one hour of collection. Next, the samples were 
centrifuged at 1500 × g for 10 min., and serum was gently 
separated and stored at –80ºC, until used. Free IGF-1 con-
centrations were tested with immunoenzymatic ELISA using 
commercially available kits (R&D): Human IGF-I Immunoas-
say (sensitivity 0,056ng/mL), according to the manufac-
turer’s protocol. Absorbance was measured at 450nm in the 
ELx 808 reader. The results are expressed as ng/mL.
Statistical analyses
Statistical analyses were carried out using the following 
tests: 
• the Shapiro-Wilk W to test the distribution for normality;
• T Student test to test quantitative parameters between 
2 groups with normal distribution and homogeneity of 
variance (Levene, Brown and Forsythe tests);
• U Mann Whitney to test quantitative parameters be-
tween 2 groups with non-normal distribution or groups 
with statistically significantly different sample size (Chi² 
test was used to check equality of group proportions);
• ANOVA rang Kruskal-Wallis to test quantitative param-
eters between more than 2 groups with non-normal 
distribution or groups with statistically significantly dif-
ferent sample size (Chi² test was used to check equality 
of group proportions); 
• Pearson’s correlation coefficient for normally distributed 
variables and Spearman’s rank correlation for non-nor-
mally distributed quantitative variables;
• Independent Pearson’s chi2 to compare qualitative vari-
ables between 2 groups. 
Statistical analysis was performed using STATISTICA 6.0, 
and the p-value of < 0.05 was considered as statistically 
significant.
RESULTS
Mean patient age in the study group was 50 years. Mean 
BMI was 26.83 kg/m2. Forty-nine (70%) patients from the 
study group had normal menses and 21 (30%) were post-
menopausal. As far as parity was concerned, the study group 
included 20 (28.57%) primiparas, 40 (57.14%) multiparas, 
and 10 (14.29%) nulliparas (Tab. 1). 
No statistically significant differences in basic patient 
characteristics (age, BMI, parity, menopausal status and 
concomitant diseases) between the study group and con-
trols were found (Tab. 1). 
Out of 70 patients with OC, 37 (52.86%) were diagnosed 
with serous carcinoma, 5 (7.14%) with undifferentiated car-
cinoma, 8 (11.43%) with clear-cell carcinoma, 3 (4.29%) with 
seromucinous carcinoma, 7 (10%) with mucinous carcinoma, 
and 10 (14.29%) with endometrioid carcinoma (Tab. 2). The 
tumor was well-differentiated (G1) in 7 (10%), moderately-
-differentiated (G2) in 21 (30%), and poorly-differentiated 
(G3) in 42 (60%) women. As a result, 10 (14.29%) patients 
were diagnosed with stage I, 38 (54.29%) with stage III, and 
22 (31.43%) with stage IV FIGO OC. No grade II FIGO cancer 
cases were found (Tab. 2).
Serum free IGF-1 levels were statistically significantly 
higher in the OC women as compared to the control group 
(Tab. 3). Significantly higher levels of IGF-1 were particularly 
pronounced in premenopausal OC women (Tab. 4). There 
was no statistically significant relationship between serum 
IGF-1 levels in OC women and tumor type, tumor differen-
tiation, disease stage, and correlation of Ca125 or height in 
OC patients (Tab. 5–9).
DISCUSSION
Elevated serum IGF-1 levels in OC patients suggest its 
role in the process of oncogenesis. Both, in vitro and in vivo 
studies indicate that the local IGF-1 system is involved in the 
induction of tumor cell proliferation, invasion and neoan-
giogenesis [2–5]. Various sources have reported IGF-1 ove-
rexpression in both, tumor tissues of OC and tumor-derived 
fluid [6–9]. Researchers, inspired by the results of OC cell and 
tissue tests, started to investigate serum IGF-1 in women 
with OC. However, the number of these studies is limited, 
and the results remain inconsistent. 
Lukanova et al., in a multi-center prospective study in 
395 women, reported a higher risk of OC in subjects with 
elevated serum IGF-1 levels, who were < 55 years of age 
at the time of diagnosis. They did not observe such a rela-
tionship for the entire study group, regardless of their age, 
or for women aged ≥ 55 at the time of OC diagnosis. All 
women < 55 at the time of OC diagnosis were pre-meno-
pausal at the time of blood collection [10]. These findings are 
consistent with the report of Peeters et al., who confirmed 
the hypothesis of Lukanova suggesting the involvement of 
serum IGF-1 in the carcinogenesis of ovarian cancer. They 
reported an increased risk for OC in women aged ≤ 55 at the 
time of diagnosis. The outcomes were particularly unambi-
guous for women who were pre-menopausal at the time of 
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blood collection. These authors did not find elevated risk 
for OC in women aged > 55 at the time of diagnosis [11]. 
Although Tas et al., did not find statistically significant 
differences in serum IGF-1 levels in women with OC as com-
pared to non-cancer patients, they reported statistically 
significantly higher serum IGF-1 levels in women < 55 as 
compared to older patients. [12] Similarly, serum IGF-1 ana-
lysis in breast cancer (BC) patients showed increased levels 
in premenopausal women with BC as compared to their 
healthy premenopausal peers. In most publications, ho-
wever, no such regularity was observed in postmenopausal 
Table 1. Statistical analysis of patient characteristics in the study and control groups
Parameter Study group (n = 70) Control group (n = 50) Test p
Age 
Mean
Min. – max.
Median
SD
 
50 years
26–85 years
49 years
 ± 10.80 years
 
53.61 years
45–70 years
52 years
 ± 6.47 years 
Cochran  
and Cox = –1.22547  > 0.05
BMI 
Mean
Min. – max.
Median
SD
26.83 kg/m2
16.02–41.16 kg/m2
26.57 kg/m2
 ± 5.54 kg/m2
27.51 kg/m2
20.55–40.04 kg/m2
26.25 kg/m2
 ± 4.56 kg/m2
U M–W = –0.590871  > 0.05
Menopausal status
Menstruating
Post-menopausal
49 (70%)
21 (30%)
30 (60%)
20 (40%)
Chi2 Pearson = 
1.296697  > 0.05
Parity
Nulliparas
Primiparas 
Multiparas
10 (14.29%)
20 (28.57%)
40 (57.14%)
4 (8%)
16 (32%)
30 (60%)
Chi2 Pearson = 
1.978776  > 0.05
Comorbidities
None
Cardiovascular diseases
Cardiovascular diseases & DM
DM
41 (58.57%)
22 (31.43%)
6 (8.57%)
1 (1.43%)
27 (54%)
18 (36%)
5 (10%)
0 (0%)
Chi2 Pearson = 
1.069641  > 0.05
BMI — body mass index, DM — diabetes mellitus, SD — standard deviation, U M–W — U Mann Whitney test
Table 2. Clinical and pathological characteristics of the study group
Characteristics Study group (n = 70)
Histological type
Serous carcinoma
Undifferentiated carcinoma
Clear cell carcinoma
Seromucinous carcinoma
Mucinous carcinoma 
Endometrioid carcinoma
37 (52.86%)
5 (7.14%)
8 (11.43%)
3 (4.29%)
7 (10%)
10 (14.29%)
Grading
G1
G2
G3
7 (10%)
21 (30%)
42 (60%)
FIGO stage
I
II
III
IV
10 (14.29%)
0 (0.00%)
38 (54.29%)
22 (31.43%)
Table 3. Statistical analysis of serum free IGF-1 levels in OC patients 
and controls
IGF-1 [ng/mL] Control group Study group 
No. of patients 50 70
Min 4.40 5.00
Max 18.60 21.00
Median 9.90 13.40
Arithmetical mean 10.00 12.98
Standard deviation 4.38 4.61
Asymmetry coefficient 0.52 –0.29
Statistical analysis T Student Test = 2.362432;  p < 0.05 (p = 0.022088)
Table 4. Statistical analysis of serum IGF-1 levels in OC women 
(premenopausal) and controls (premenopausal)
IGF-1 [ng/mL] Control group (premenopausal)
Study group
(premenopausal)
No. of patients 30 49
Min 4.40 9.60
Max 18.60 21.00
Median 11.20 15.20
Arithmetical mean 11.16 15.21
Standard deviation 4.80 3.01
Asymmetry coefficient 0.30 –0.60
Statistical analysis T Student Test = 2.986286; p < 0.05 (p = 0.005476)
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women, whose serum IGF-1 levels did not show statistically 
significant differences [13]. 
Our study team found that most OC patients who had 
a serum IGF-1 clearance were premenopausal (49 out of 
70). Although no statistically significant differences in me-
nopausal status and age were found, serum IGF-1 levels of 
premenopausal OC women as compared to premenopau-
sal healthy peers were evaluated. As a result, significantly 
higher levels of serum IGF-1 were observed in patients with 
OC as compared to controls. The difference was even more 
apparent than in cases when the menopausal status was not 
taken into consideration, which may be consistent with the 
hypothesis that serum IGF-1 is involved in the biology of OC 
mainly in premenopausal women. There have been several 
attempts to explain this fact. Although IGF-1 can be produ-
ced by various tissues, the liver, whose cells synthesize this 
factor in response to the growth hormone (GH), remains the 
primary source of serum IGF-1. It has been demonstrated that 
IGF-1 production is reduced with age by the liver, possibly 
due to a weaker response to pituitary GH expression [14]. 
With aging, serum IGF-1 is less affected by the GH/IGF-1 axis 
than in adolescence [15]. Some researchers have reported 
an increased risk for the development of OC in taller women, 
which could indirectly account for the theory in question [16]. 
Namely, the achieved height is strongly correlated with the 
level of serum IGF-1 in puberty, i.e. in young women, but later 
there is no correlation [17]. It would therefore be possible 
for taller women to be exposed to higher levels of serum 
IGF-1 during puberty and at a young age, which could result 
in an elevated risk for cancer transformation to OC. However, 
researchers the possible correlation between the increase in 
height and the risk for developing OC has been subject to 
much heated debate [18]. In our study, the height of OC and 
non-cancer patients did not differ significantly and thus, this 
parameter was not associated with OC and did not affect 
the obtained results. Similarly, the analysis of free serum 
IGF-1 levels in OC patients and their height also did not reveal 
a significant correlation between these parameters. Another 
explanation for the modification of serum IGF-1 level based 
on age and menopausal status may be the hypothesis sug-
gesting the presence of high levels of estrogen in women 
of reproductive age. Endogenous estrogen-dependent, 
Table 5. Statistical analysis of serum free IGF-1 concentrations in 
patients with OC versus histological tumor type
IGF-1[ng/mL]
Histological tumor type
Serous carcinoma Other
No. of patients 37 33
Min 5.00 5.70
Max 21.00 19.00
Median 12.85 13.80
Arithmetical mean 12.34 13.78
Standard deviation 5.14 3.92
Asymmetry coefficient 0.03–0.77
Statistical analysis T Student Test = 0.826354; p > 0.05
Table 6. Statistical analysis of serum free IGF-1 levels in patients 
with OC versus tumor grade 
IGF-1[ng/mL]
Tumor grade
G1 G2 G3
No. of patients 7 21 42
Min 5.70 5.00 5.40
Max 16.60 21.00 19.50
Median 15.30 14.05 13.40
Arithmetical mean 12.53 13.28 12.92
Standard deviation 5.95 5.58 4.24
Asymmetry coefficient –1.64 –0.13 –0.39
Statistical analysis Kruskal Wallis ANOVA = 0.044297; p > 0.05
Table 7. Statistical analysis of serum free IGF-1 concentrations in 
patients with OC versus FIGO stage (2014)
IGF-1[ng/mL]
FIGO Stage
I II III IV
No. of patients 10 0 38 22
Min 5.70 – 5.00 5.40
Max 16.60 – 21.00 19.00
Median 9.30 – 13.50 14.25
Arithmetical mean 10.53 – 13.56 13.01
Standard deviation 5.56 – 4.90 4.37
Asymmetry coefficient 0.95 – –0.16 –0.71
Statistical analysis Kruskal Wallis ANOVA = 0.622699; p > 0.05
Table 8. Statistical analysis of the correlation (Pearson Correlation): 
between serum free IGF-1 concentration in OC patients and their height 
IGF-1
Growth
R (X, Y) p
0.013369 p > 0.05
R (X, Y) — pearson's correlation coefficient
Table 9. Statistical analysis of the correlation between serum free 
IGF-1 concentration and Ca125 in patients with OC
Parameter
Ca 125
R p
IGF-1 –0.019468 p > 0.05
R — spearman’s rank 
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elevated serum IGF-1 levels have been demonstrated in 
the perovulatory period in women with normal menstrual 
cycles. Furthermore, after the menopause, a decrease not 
only in total serum IGF-1 but also in the concentration of its 
biologically active form, i.e. free IGF-1, have been observed 
[10, 11, 19–21]. On the other hand, some sources reported no 
changes in serum IGF-1 levels depending on different phases 
of the menstrual cycle, and found no correlation between 
IGF-1 levels and endogenous serum estrogen concentrations 
[22–24]. This hypothesis is therefore not an ideal explanation 
for the association between elevated serum IGF-1 levels and 
an increased risk for OC in young women. 
Lower serum IGF-1 levels in OC patients as compared 
to women with benign tumors and/or non-tumor women 
have also been reported by some authors [25–29]. Other 
researchers did not observe any statistically significant dif-
ferences in serum IGF-1 levels in OC women as compared to 
non-cancer patients, and did not report any higher serum 
IGF-1-dependent risk for the development of OC [12, 30]. 
However, these studies were conducted either in postme-
nopausal women or their menopausal status was as shown 
in the abovementioned analysis, and our findings have 
implications for the change in IGF-1 levels [10–12]. More-
over, these authors did not account for the possibility of 
cardiovascular diseases (common in older, postmenopausal 
patients) in the investigated populations, what might be 
a serious study limitation due to a proven link between 
lowered serum IGF-1 level and these pathologies [31, 32]. 
It cannot be ruled out that OC women were more likely to 
suffer from cardiovascular diseases. As a result, the reported 
lower serum IGF-1 levels in OC patients did not result de facto 
from this pathology but a comorbid cardiovascular disease 
[25, 26, 29]. Moreover, Flyvbjerg et al., did not include data 
on BMI, diabetes mellitus (DM), and hormone replacement 
therapy (HRT) in their publication [25], which questions 
the reliability of the results, given the fact that both, BMI 
and DM have a proven effect on serum IGF-1 level [33, 34]. 
Numerous studies have also indicated that oral HRT leads 
to a significant decrease in serum IGF-1 levels, which is 
probably due to direct inhibition of the synthesis of this 
factor in the liver by oral estrogen [35]. We observed no 
significant differences in either, BMI values or distribution of 
comorbidities in OC patients with IGF-1 and controls. These 
parameters did not affect the results. In addition, none of 
the patients included in the study received HRT or hormonal 
contraception because it constituted an exclusion criterion.
Three other publications also reported a decrease in total 
serum IGF-1 levels in OC patients [27, 28, 36]. However, these 
studies did not account for the menopausal status, age, and 
the possibility of cardiovascular diseases in the investigated 
populations. Therefore, it remains unknown whether this 
factor affected their findings. In addition, Dal Maso et al., 
observed a reduced level of total serum IGF-1 in OC women 
as compared to controls, while serum free IGF-1 levels were 
similar in both groups [27]. It follows that the percentage 
of serum free IGF-1 was significantly higher as compared to 
total serum IGF-1 in OC women versus controls. However, 
due to the inaccurate analysis by the authors, it is difficult to 
draw clear conclusions from their work [27]. Baron-Hay et al., 
and Shah et al., also did not include data on BMI, DM, HRT 
or hormonal contraception, thus rendering their analyses 
unreliable [28, 36]. In addition, as was claimed by Tworoger 
et al., considering the biology of OC and the proven direct 
involvement of IGF-1 in the development of this tumor in 
experimental studies on OC, an inverse correlation between 
serum IGF-1 and the process of carcinogenesis of OC seems 
unlikely [30]. Also, these authors found no relationship be-
tween serum IGF-1 levels and the risk for OC, even in cases of 
OC diagnosis in women < 55 years of age. However, despite 
a large sample size, the group of women < 55 years of age 
and diagnosed with OC consisted of only 59 patients, which 
was a limitation for the analysis. In addition, they did not 
specify the menopausal status of these 59 women at the 
time of blood collection, which might have had a significant 
impact on the obtained results [30]. One might speculate 
that most of the 59 subjects were in fact postmenopausal at 
the time of blood collection, which would have significantly 
affected the final results. 
No significant correlations between the level of serum 
free IGF-1 in OC women and clinical and pathological para-
meters were found, which is consistent with all publications 
included in the study [10–12, 25–30].
CONCLUSIONS
IGF-1 is most likely involved in the etiology of OC. Unfor-
tunately, the level of serum IGF-1 is influenced by numerous 
factors both, genetic and exogenous, such as diet, exercise, 
medication, BMI, chronic diseases (DM, cardiovascular and 
other), and age [14, 15, 29, 31–35, 37]. In addition, not all 
factors which influence the regulation of serum IGF-1 have 
been fully elucidated. However, based on our results and the 
available literature, it seems safe to conclude that the level 
of IGF-1 in OC tissues is probably affected by endocrine and 
autocrine regulation, which is consistent with the results 
obtained by Brokow and Conover [6, 38]. Studies conducted 
to clarify the role of IGF-1 (both, locally synthesized and pe-
ripherally circulating serum) in the biology of breast cancer, 
have confirmed the role of this factor in the oncogenesis of 
this tumor [35]. The carcinogenesis of OC may be analogous 
and the IGF-1 present in the serum is involved in the car-
cinogenesis of this tumor mainly in young, menstruating 
women. In older, postmenopausal women, local synthesis 
of IGF-1 and the other components of the autocrine loop of 
the IGF-1 system is likely to play a greater role.
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